Has Mohammed Bayasi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $128,107 in general payments to Mohammed Bayasi, MD across 561 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mohammed Bayasi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mohammed Bayasi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mohammed Bayasi, MD

Pulmonary Disease · Grand Blanc, MINPI 1528170073

Payments from drug & device makers

$128,107in general payments, 2019–2025

Across 561 payments — averaging $228.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$114K
Viiv Healthcare Company$3K
Pulmonx Corporation$1K
AstraZeneca$1K
Boehringer Ingelheim Canada Ltd.ltee$1K
Jazz Pharmaceuticals Inc.$623
plus $6K from 40 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	179	$113,864
Viiv Healthcare Company	2	$3,482
Pulmonx Corporation	8	$1,382
AstraZeneca	69	$1,373
Boehringer Ingelheim Canada Ltd.ltee	2	$1,176
Jazz Pharmaceuticals Inc.	12	$623
Boehringer Ingelheim	26	$579
Actelion Pharmaceuticals US, Inc.	20	$576
Sanofi	25	$433
United Therapeutics Corporation	17	$396
Regeneron Healthcare Solutions, Inc.	16	$323
Mylan Specialty L.p.	15	$306
Insmed, Inc.	14	$292
Harmony Biosciences LLC	12	$287
Takeda Pharmaceuticals U.S.A., Inc.	11	$225
Novartis	13	$212
Baxter Healthcare	7	$201
Cook Incorporated	1	$200
Bayer	10	$178
CSL Behring	8	$173
Philips North America LLC	12	$171
Mallinckrodt Hospital Products Inc.	9	$168
Resmed Corp	9	$167
Recor Medical Inc	1	$125
Axsome Therapeutics, Inc.	5	$116
Genentech USA, Inc.	5	$99
Johnson & Johnson	6	$98
Grifols USA, LLC	5	$88
Inspire Medical Systems, Inc.	2	$88
Gilead	6	$86
Amgen	4	$82
AbbVie(2 entities)	5	$77
Teva Pharmaceuticals USA, Inc.	4	$76
Merck	2	$51
Verona Pharma, Inc.	3	$49
Paratek Pharmaceuticals, Inc.	2	$40
Electromed, Inc.	2	$33
Circassia Inc.	2	$32
Shire North American Group Inc	2	$32
Advanced Respiratory, Inc	2	$31
Vifor Pharma, Inc.	1	$27
Vapotherm Inc	1	$21
Sunovion Pharmaceuticals Inc.	1	$20
Melinta Therapeutics, LLC	1	$17
Mallinckrodt Enterprises LLC	1	$16
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$15

How this compares

$128,107 in reported general payments places this provider in the 90th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan →

Medicare billing

Part B allowed, 2024

$291,945

Medicare patients

731

Services billed

2,990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Grand Blanc

Njira LugogoAnn Arbor$12.9M
Timothy BlackwellAnn Arbor$2.5M
Kevin FlahertyAnn Arbor$2.3M
Meilan HanAnn Arbor$1.8M
Gary FergusonLivonia$1.5M
Justin OldhamAnn Arbor$1.4M
Robert PaineAnn Arbor$1.3M
Irina ShanidzeFarmington Hills$1.2M
Oscar Parodi Ortiz de VillateWarren$1.1M
Yvonne HuangAnn Arbor$1.1M

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →